Publikationen in Zusammenarbeit mit Forschern von Eli Lilly and Company (45)

2023

  1. RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome

    Clinical Lung Cancer, Vol. 24, Núm. 5, pp. 415-428

  2. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results

    ESMO Open, Vol. 8, Núm. 4

2022

  1. Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study

    npj Breast Cancer, Vol. 8, Núm. 1

  2. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer

    Future oncology (London, England), Vol. 18, Núm. 28, pp. 3133-3141

2021

  1. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer

    Clinical Cancer Research, Vol. 27, Núm. 4, pp. 992-1003

  2. RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non⇓small cell lung cancer

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5258-5271

2019

  1. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

    The Lancet Oncology, Vol. 20, Núm. 8, pp. 1109-1123

2018

  1. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

    Journal of Thoracic Oncology, Vol. 13, Núm. 2, pp. 165-183

  2. EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study

    Journal of Thoracic Oncology, Vol. 13, Núm. 2, pp. 228-236

  3. Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non–Small-Cell Lung Cancer

    Clinical Lung Cancer, Vol. 19, Núm. 2, pp. 130-138.e2

  4. Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

    Current Medical Research and Opinion, Vol. 34, Núm. 5, pp. 865-871

  5. KRAS-Mutant non-small cell lung cancer: From biology to therapy

    Lung Cancer, Vol. 124, pp. 53-64

  6. Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

    Clinical Lung Cancer, Vol. 19, Núm. 4, pp. 331-339

  7. Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non–Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care

    Clinical Lung Cancer, Vol. 19, Núm. 6, pp. e823-e830

  8. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell Lung Cancer (RELAY): Phase Ib Results

    Clinical Lung Cancer, Vol. 19, Núm. 3, pp. 213-220.e4

  9. Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis

    Thrombosis Research, Vol. 167, pp. 50-56

2017

  1. A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer

    Lung Cancer, Vol. 108, pp. 212-216

  2. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer

    Lung Cancer, Vol. 104, pp. 45-51

  3. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

    Annals of Oncology, Vol. 28, Núm. 12, pp. 2932-2942

  4. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer

    Lung Cancer, Vol. 112, pp. 181-187